UEEC - United Health Products, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.6400
-0.0200 (-1.20%)
As of 1:38PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.6600
Open1.7400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.6200 - 1.7700
52 Week Range0.3000 - 2.5500
Volume58,053
Avg. Volume249,980
Market Cap289.606M
Beta (3Y Monthly)0.89
PE Ratio (TTM)N/A
EPS (TTM)-0.0280
Earnings DateJan 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    United Health Products Appoints Dr. Gerard Abate Chief Medical Director

    HENDERSON, Nev., Sept. 06, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for.

  • GlobeNewswire

    Recent Publicity About United Health Products

    United Health Products, Inc. (UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose, today announced that over the past 2 ½ weeks articles have been published about UHP, without UHP’s review or participation, by persons unrelated to UHP who disclosed in those articles that they were in a short position in UHP stock. The Company is examining with counsel and advisors those publications and assessing the matter. UHP discloses information about our Company in various ways: Filing reports with the Securities Exchange Commission, disseminating press releases and holding announced shareholder/investor calls from time-to-time.

  • GlobeNewswire

    Corrected News Release - United Health Products Announces Completion of Human Trial Study

    HENDERSON, Nev., Aug. 28, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose.

  • GlobeNewswire

    United Health Products Announces Completion of Human Trial Study

    HENDERSON, Nev., Aug. 28, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose.

  • GlobeNewswire

    United Health Products Announces Completion of Pathology and Study of Preclinical Bone Application of HemoStyp®

    United Health Products, Inc. (UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it had received the pathology results of a preclinical animal study to assess the effect of HemoStyp on the bone. This study and indication is independent of the current PMA application and will potentially allow UHP acess to a new and significant market opportunity. UHP believes that these preliminary results demonstrate the safe application of HemoStyp in orthopedic procedures.

  • GlobeNewswire

    United Health Products Files New Patent Application Method of Forming and Using a Hemostatic Hydrocolloid

    United Health Products, Inc. (UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, today announced that it has filed a patent application covering methods of forming and using a hemostatic material, and more specifically, methods of forming and using a hemostatic hydrocolloid that is formed into a gel, foam or spray used to control bleeding and oozing from a variety of wounds. Upon approval of the new patent, this will allow for the HemoStyp hydrocolloid to act as a conduit to transfer other properties associated with the treatment of wounds within the hydrocolloid. “This enables HemoStyp to be bundled as a suite of multiple products for surgical and wound care applications,” said Louis Schiliro, COO, UHP.

  • GlobeNewswire

    United Health Products Announces the Completion of Human Trial Surgery Enrollment

    HENDERSON, Nev., Aug. 05, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for.

  • GlobeNewswire

    United Health Products Issues Shareholder Update

    It expects to complete enrollment and all surgical procedures for its human clinical trial on or around mid-July 2019. David W. Ramey DVM has prepared a presentation —How to Use a Hemostatic Gauze Product to Help Control Bleeding in Clinical Settings in the Horse— which will be published in the Journal of Veterinary Emergency and Critical Care.

  • GlobeNewswire

    United Health Products Announces Completion of IQVIA Independent Market Assessment for HemoStyp® in Support of Review of Strategic Alternatives

    HENDERSON, Nev., May 07, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the.

  • GlobeNewswire

    United Health Products Retains IQVIA to Conduct U.S. Market Commercialization Study of HemoStyp® in Support of Société Générale’s Strategic Review

    HENDERSON, Nev., April 24, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or “the company”), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for.

  • GlobeNewswire

    United Health Products Announces 2018 Results

    United Health Products, Inc. (UEEC) (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today filed its Form 10-K for the year ended December 31, 2018. Douglas K. Beplate, President and CEO said, “2018 was the most important year to date in our company’s development: we shifted our corporate focus to achieving FDA Class III approval for our products in human surgical applications.  We believe that gaining access to this $3.4 billion segment of the hemostatic gauze market is the best path to creating value for our shareholders and so we have devoted our resources fully to that objective. In February 2018, the Company completed and submitted to the U.S. Food and Drug Administration (“FDA”) all materials relevant for the pre-market approval (“PMA”) for HemoStyp under the FDA’s new and innovative CtQ Pilot-Program as a Class III application for internal surgical procedures.

  • GlobeNewswire

    United Health Products to Hold Conference Call on December 20, 2018 to Discuss Recent Corporate Developments and Provide Year End Update

    HENDERSON, Nev., Dec. 17, 2018 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), a manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for.

  • GlobeNewswire

    United Health Products Retains Legal Counsel Ruskin Moscou Faltischek P.C to Assist in Strategic Review

    United Health Products, Inc. (UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it had retained Ruskin Moscou Faltischek P.C. to assist it and Société Général in its previously announced Review of Strategic Alternatives. In connection with the FDA PMA Class III approval process for HemoStyp, UHP has been contacted by a number of medical technology companies that are active in the surgical equipment and hemostatic products sectors, and who have expressed an interest in the Company’s products and business strategy. In response to these inbound contacts, and to maximize shareholder value, the Company’s board of directors has determined to conduct a review of strategic alternatives, which include a potential sale of the Company, joint venture or other commercial partnership, or a standalone growth plan.